C4 Therapeutics (CCCC) Free Cash Flow Growth (1y) (2020 - 2026)
Powered by 
Analysis
C4 Therapeutics (CCCC) Free Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 9.25% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | -38.10% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 38.94% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 96.00% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 152.82% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 31.57% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 58.53% |
| 10 | C4 Therapeutics | 489.46 Mn | 235.80 Mn | - | 86.96% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 86.96% |
| Mar 31, 2026 | 9.85% |
| Dec 31, 2025 | -23.58% |
| Sep 30, 2025 | -30.63% |
| Jun 30, 2025 | -138.85% |
| Mar 31, 2025 | -83.71% |
| Dec 31, 2024 | 25.81% |
| Sep 30, 2024 | 22.96% |
| Jun 30, 2024 | 73.29% |
| Mar 31, 2024 | 46.26% |
| Dec 31, 2023 | 21.07% |
| Sep 30, 2023 | -8.87% |
| Jun 30, 2023 | 23.46% |
| Mar 31, 2023 | -25.95% |
| Dec 31, 2022 | -18.77% |
| Sep 30, 2022 | -56.64% |
| Jun 30, 2022 | -37.10% |
| Mar 31, 2022 | -4.33% |
| Dec 31, 2021 | -17.80% |
| Sep 30, 2021 | -25.05% |